# A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

> **NCT06109272** · PHASE2,PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 660 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Livmoniplimab
- **DRUG:** Budigalimab
- **DRUG:** Durvalumab
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT06109272
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109272, "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06109272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*